Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?
News & Analysis: Qiagen N.V.
The molecular diagnostics company blew past Wall Street's top- and bottom-line expectations in the first quarter for one main reason.
Multiple companies have gained regulatory approvals in recent days.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
There's no shortage yet, but the FDA is working to address supply issues with a key component of COVID-19 diagnostics tests.
The diagnostic-test maker is being acquired for $11.5 billion.
The stock market was turbulent Tuesday morning.
The world's leading provider of scientific tools will buy QIAGEN and its growing menu of molecular diagnostic products.
Amid ever-rising numbers of infected individuals, Qiagen believes it offers a quick solution to expedite testing for the virus.
QGEN earnings call for the period ending December 31, 2019.